A 25-Year-Old Woman with a High-Risk Large and Occlusive Pulmonary Embolism, Later Diagnosed with Primary Antiphospholipid Syndrome and Hyperhomocysteinemia: A Case Report

Muñoz-Moreno J.-M.; Ramos-Yataco A.; Salcedo-Davila E.; Alcalde-Loyola C.; Halanoca-Quispe C.; Requena-Armas C. · American Journal of Case Reports (2023) · DOI: 10.12659/ajcr.939078

Resumen

Objective: Background: Case Report: Conclusions: Challenging differential diagnosis High-risk pulmonary embolism (PE) occurs when the pulmonary circulation is suddenly occluded by a throm-bus and is a life-threatening medical emergency. In young and otherwise healthy individuals, there may be un-diagnosed underlying risk factors for PE that require investigation. This report presents the case of a 25-year-old woman admitted as an emergency with a high-risk large and occlusive PE, later diagnosed with primary antiphospholipid syndrome (APS) and hyperhomocysteinemia. A 25-year-old woman presented with sudden-onset dyspnea after elective cholecystectomy. One year earlier, the patient had lower limb deep vein thrombosis without an identified predisposing cause, and she received anticoagulation for 6 months. On physical examination, she had right leg edema. Laboratory tests revealed el-evated levels of troponin, pro-B-type natriuretic peptide, and D-dimer. Computed tomography pulmonary an-giography (CTPA) demonstrated a large and occlusive PE, and an echocardiogram showed right ventricular dys-function. Successful thrombolysis was performed with alteplase. On repeat CTPA, a significant reduction in filling defects in the pulmonary vasculature was observed. The patient evolved uneventfully and was discharged home on a vitamin K antagonist. Due to unprovoked recurrent thrombotic events, suspicion of underlying thrombo-philia was raised, and hypercoagulability studies confirmed primary APS and hyperhomocysteinemia. This report presents the case of a life-threatening high-risk PE in a previously healthy young woman and highlights the importance of emergency management followed by investigation and treatment of underlying risk factors for venous thromboembolism, including APS and hyperhomocysteinemia. © Am J Case Rep, 2023.

Instituciones: Universidad Nacional Mayor de San Marcos